Loading...
•
Sep 30, 2023
Dynavax Q3 2023 Earnings Report
Reported financial results and provided a business update for the quarter ended September 30, 2023.
Key Takeaways
Dynavax reported a record quarter of HEPLISAV-B revenue, driven by market share growth and expansion of the adult hepatitis B market. The company is focused on advancing its pipeline of innovative vaccine candidates and pursuing strategic opportunities to accelerate growth. Full year HEPLISAV-B net product revenue guidance was raised to $210 - $220 million.
Generated quarterly HEPLISAV-B® vaccine net product revenue of $62.3 million, a 66% year-over-year increase
Raising full year HEPLISAV-B net product revenue guidance to $210 - $220 million, compared to prior range of $200 - $215 million
Cash and investments increased to $720 million at quarter end
Expects positive free cash flow for full year
Revenue by Segment
Forward Guidance
Full year 2023 financial guidance has been revised.
Positive Outlook
- HEPLISAV-B net product revenue between approximately $210 - $220 million, compared to the prior range of approximately $200 - $215 million.
- Research and development expenses between approximately $50 - $60 million, compared to the prior range of approximately $55 - $70 million.
- Selling, general and administrative expenses between approximately $145 - $155 million, compared to the prior range of approximately $135 - $155 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...